Fundraising Fox
/Companies
Sign in

Synaptogenix

NASDAQ: TAOX

New York, US · Delaware corporation

Find your way into Synaptogenix

Sign up to see every warm intro you have to Synaptogenix

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Synaptogenix team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

TAO Synergies (Nasdaq: TAOX) is a publicly traded investment vehicle focused exclusively on Bittensor (TAO), a token for decentralized AI, which it accumulates and stakes to generate revenue. The company aims to give shareholders exposure to the decentralized AI ecosystem and deliver long-term capital appreciation.

AI & Machine LearningBiotechCrypto & Web3Fintech

Founders & leadership

AJ
Alan J. TuchmanExecutive
RW
Robert WeinsteinExecutive
DADaniel Alkon
Daniel AlkonExecutive
GP
George PerryNamed on SEC filing

Board

BT
Bruce T. BernsteinBoard director
JS
Joshua SilvermanBoard director
JL
Jonathan L. SchechterBoard director
WS
William SingerBoard director

Reported raises · per SEC filings

Form D private placements

$46.2M disclosed across 5 of 6 rounds · 1900–2025

▶$11MraisedOct 2025 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • BRUCE BERNSTEINDirector
  • WILLIAM SINGERDirector
  • JOSHUA SILVERMANExecutive Officer, Director
  • ROBERT WEINSTEINExecutive Officer
  • ROBERT EPHRONDirector
Offering amount
$11M
Amount sold
$11M
Sales commissions
$880K
Placement agents
GP NURMENKARI INC.
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedJun 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JONATHAN L. SCHECHTERDirector
  • BRUCE T. BERNSTEINDirector
  • JOSHUA SILVERMANExecutive Officer, Director
  • WILLIAM SINGERDirector
  • ROBERT WEINSTEINExecutive Officer
Offering amount
$5.5M
Amount sold
$5.5M
Sales commissions
$385K
Placement agents
GP NURMENKARI INC.
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedSep 2024 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce T. BernsteinDirector
  • Alan J. TuchmanExecutive Officer, Director
  • Joshua SilvermanDirector
  • Robert WeinsteinExecutive Officer
  • Daniel AlkonExecutive Officer, Director
  • Jonathan L. SchechterDirector
  • William SingerDirector
Offering amount
$3.2M
Amount sold
$3.2M
Sales commissions
$224.5K
Placement agents
GP Nurmenkari Inc.
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.5MraisedJun 2021 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan L. SchechterDirector
  • Bruce T. BernsteinDirector
  • William SingerDirector
  • George PerryDirector
  • Alan J. TuchmanExecutive Officer, Director
  • Joshua N. SilvermanDirector
  • Daniel A. AlkonExecutive Officer, Director
  • Robert WeinsteinExecutive Officer
Offering amount
$12.5M
Amount sold
$12.5M
Sales commissions
$1.1M
Placement agents
Katalyst Securities LLC
First sale
Jun 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14MraisedFeb 2021 · 66 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan L. SchechterDirector
  • George PerryDirector
  • Bruce T. BernsteinDirector
  • William SingerDirector
  • Joshua N. SilvermanDirector
  • Daniel A. AlkonExecutive Officer, Director
  • Alan J. TuchmanExecutive Officer, Director
  • Robert WeinsteinExecutive Officer
Offering amount
$14M
Amount sold
$14M
Sales commissions
$1.4M
Placement agents
GP Nurmenkari Inc., Katalyst Securities LLC
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Synaptogenix do?
TAO Synergies (Nasdaq: TAOX) is a publicly traded investment vehicle focused exclusively on Bittensor (TAO), a token for decentralized AI, which it accumulates and stakes to generate revenue. The company aims to give shareholders exposure to the decentralized AI ecosystem and deliver long-term capital appreciation.
How much funding has Synaptogenix raised?
Synaptogenix has disclosed $46.2M raised across 5 of its 6 known rounds.
Where is Synaptogenix headquartered?
Synaptogenix is headquartered in New York, US.